36.6 F
New York
Wednesday, January 27, 2021

Inovio Inc. [NASDAQ: INO] COVID-19 Vaccine Candidate Shows Promising Result

Must read

JPMorgan [NYSE: JPM] Announced To Initiate A Digital Retail Bank In The United Kingdom

JPMorgan Chase revealed that the company will launch a new digital retail bank in the United Kingdom offering the customer of the region...

Humanigen [NASDAQ: HGEN] Announces Expansion Of Manufacturing Agreement With Ajinomoto Bio-Pharma

Humanigen Inc revealed that the company has extended the manufacturing agreement with  Ajinomoto BioPharma to support the fill-finish of Lenzilumab. The Lenzilumab is...

Synchrony [NYSE: SYF] Announced To Purchase Allegro Credit

Synchrony Financials revealed that the company entered into a definitive contract to Purchase Allegro Credit. Allegro Credit's customer base and merchant network will...

Vericel Corp [NASDAQ: VCEL] Names Joe Mara As The New CFO

Vericel Corporation revealed that the company has named Joe Mara as the CFO of the company. He has over more than 20 years...

Inovio Pharmaceuticals, Inc. [NASDAQ: INO] revealed today that its COVID-19 vaccine candidate has shown a positive result. INO-4800, a COVID-19 DNA vaccine candidate has proven to be useful as it has protected the non-human primates from live virus under the challenge of 13 weeks from last vaccination.

During the trial, INO-4800 decreased the viral infection in both the lower lungs and nasal passages in macaques that received two doses of INO-4800 four weeks apart. Then 13 weeks after the second dose, they encountered with live virus.

As the viral load decreased during this timeframe highlight an important durable effect mediated by INO-4800. This is the first time a vaccine candidate showed positive results in protecting non-human primates.

Inovio’s shares have closed green during the trading of Thursday and exhibited a change of 12.65% and up +21.95. It has previously opened at $21.10 and closed at $21.95.

Inovio had a trading volume of 16.94 million as compared to the average volume of 36.57 million. In the past 52-weeks of trading, this company’s stocks have changed between the low of $1.91 and a high of $33.79.

If we look at its profitability, its return on assets (ROA) is -61.40%, return on investment (ROI) is -137.90%, and return on equity (ROE) of -178.40%. Turning our focus on liquidity, its current ratio and quick ratio is 8.50. Inovio has a total market capitalization of 3.45 billion.

INO-4800 which is a DNA vaccine candidate of INOVIO is created to protect against COVID-19. This candidate is currently in the Phase 1 trial and expected to start the phase 2/3 trial in the Summer.

INO-4800’s protective results were mediated by memory T and B cell immune responses from INO-4800 vaccination. B cells are involved in the production of antibodies which recognized SARS-CoV-2 while the T cells are involved in the destruction of viral cell and also aid B cell response.

Immunization with INO-4800 has the ability to decrease the active viral replication and has the ability to reduce the severity of the infection.

More articles

Latest article

A Paychex [NASDAQ: PAYX] Subsidiary Announces Strategic Collaboration With Zoho Books

SurePayroll, a subsidiary of Paychex company revealed that the company has formed a collaboration with Zoho books. SurePAyroll is a provider of small...

MGP Ingredients [NASDAQ: MGPI] Announced To Acquire Luxco and Its Affiliate Companies

MGP Ingredients  revealed a definitive contract to purchase Luxco, Inc and its affiliated companies. Luxco is an alcohol beverage company with more than 60...

Conformis [NASDAQ: CFMS] Entered A Non-Exclusive agreement with SITES Medical

Conformis Inc revealed that the company inked a development and supply contract with sites medical. Both of the companies will work together to...

Colliers International [NASDAQ: CIGI] Announces Executive Leadership Changes For Australian Business

Colliers International  reported that the company has named Malcom Tyson as the new Chief Executive Officer. He is appointed as the CEO so...

Korn Ferry [NYSE: KFY] Announces Expansion Of Its Footprint In Russian Market

Korn Fery revealed that the company is expanding its footprint in Russia. Moreover, it is adding a high expertise team of executive search...

Haemonetics [NYSE: HAE] To Purchase Cardiva For An Upfront Payment Of $475M

Haemonetics Corporation revealed that the company has inked a definitive contract to purchase Cardiva Medical Inc. Under the contract, Haemontics will pay an...

Philips [NYSE: PHG] To Purchase Capsule Technologies For Cash Consideration Of USD 635M

Koninklijke Philip revealed that the company has inked a contract to purchase Capsule technologies. The company will pay a cash price of $636...

Thermo Fisher Scientific [NYSE: TMO] To Purchase Mesa Biotech For Approx. $450M In Cash

Thermo fisher scientific inc revealed that the company has signed a definitive contract to purchase Mesa Biotech. Thermo will pay a value price...